Dreem’s Post

We're tackling obesity and sleep apnea head-on! We're thrilled to announce today a strategic collaboration with Skye Bioscience Inc. (Nasdaq: SKYE)! This partnership will integrate advanced sleep monitoring endpoints into Skye’s upcoming CBEYOND™ Phase 2 trial of Nimacimab, a promising treatment for obesity. By incorporating our FDA 510(k)-cleared Dreem 3S EEG headband and Beacon Platform, we will to provide comprehensive insights into how Nimacimab impacts sleep quality and reduces sleep apnea in patients. This integration will enable a deeper understanding of the link between metabolic health and sleep, potentially transforming treatment paradigms for millions affected by obesity and obstructive sleep apnea. Stay tuned for more updates as we work together to revolutionize brain health and metabolic disease treatments! 🚀 Read the full press release here: https://lnkd.in/d9WET6FN #SleepHealth #ClinicalTrials #ObesityTreatment #CB1 #Healthcare #Sleepapnea #OSA #GLP1